Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma - Wikidata - wikimedia - TriplyDB

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

http://www.wikidata.org/entity/Q34034408

about

Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Overcoming T cell exhaustion in infection and cancer From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.VISTA Regulates the Development of Protective Antitumor Immunity.Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function Designing vaccines based on biology of human dendritic cell subsets Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen B7-h1 expressed by activated CD8 T cells is essential for their survival.Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.Programmed death ligand 2 in cancer-induced immune suppression.Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients Enhancement of dendritic cells as vaccines for cancer Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.PD-1 blockade enhances the vaccination-induced immune response in glioma Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.Radiotherapy and immune checkpoint blockades: a snapshot in 2016.Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.Dendritic cell subsets as vectors and targets for improved cancer therapy Dendritic cells: are they clinically relevant?Dendritic cells and immunity against cancer.Current status and future applications of cellular therapies for cancer.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?

P2860

Q26742107-17894450-DE1C-45E9-8DDA-5201B7323FF3 Q26779221-55D619D8-7E6A-49E5-B7C7-9F7836B271DB Q26829885-A8787B2B-28FB-4E19-A3F5-BFF8638BED06 Q26865532-64652C0B-DC32-449E-AE35-7981ABC8AF52 Q27002646-C6AD4366-ADC3-4374-B958-D2A7B3722B28 Q28075712-9120A54E-9B7C-4D41-AC46-7FA6F4A8366E Q28242808-324B6712-A463-4D7C-9B49-F7498BDEBDA4 Q33591239-DB1B33B6-3772-4FF6-8F89-66146D9CFFFC Q33768093-13C1AA86-76F6-432E-8AE5-03827641D9A2 Q33978040-EF799CD0-A211-4F62-953E-A62A0778E771 Q34033862-8061AFD5-FA02-4217-BC8E-443823223E3D Q34052580-E23488F6-B30D-4FDE-9501-7A70502C3517 Q34087816-DC778658-8898-4556-ACB8-D1C8F6121037 Q34289152-F0E24B1D-CEF1-4723-AF57-A8DB59E5FB61 Q34300883-B68A2752-541B-453E-9577-80F3C7A507C6 Q34658452-3DF281B6-5EC4-453A-A341-C7335441D25E Q34849409-C443B2C5-D36B-4842-BD4C-4142337ECC75 Q35107009-5C9619CB-8459-48B5-8FE5-C20226DFDD16 Q35151883-AA72ADDF-4C90-42F7-88E1-CFECF5DD6F68 Q35221521-BD618514-B6DD-438E-BC64-3968D7ABCCCF Q35328111-7E79C0DD-D07B-4793-97CC-7BA6C00050EA Q35566744-D7CF9BD3-3EBF-4968-8FC4-07B463F0E8E3 Q35802152-3A0E8A76-E1C3-419E-94FC-64D08A9CBFF5 Q35955151-CD644D87-EE1A-4E7E-958E-B83AEEF59AD8 Q35981245-F6BCF5D7-8BEB-45BC-AF55-5A2664F365FB Q36021225-78A24B9B-27D0-4AF4-BABB-DA646266AB08 Q36057487-3DDF9957-378A-4C22-83D4-A8B647E0E9DB Q36209210-A53B2A7B-D75F-4ECA-BB52-28BCB2D2B0CD Q36422292-CE5E763F-FAEF-45CB-AAD8-F65A915B45A2 Q37109193-5F52686D-DC32-4146-97D7-FC205EC840FB Q37309250-93417D30-D7C9-4754-B101-3C9431DB7A56 Q37478912-39EFA222-C5B3-4BA0-B10A-B5337D5E7D64 Q37551762-A0E68155-0AB7-4482-9BE6-F4AF38BE518F Q37564683-351209C7-DB3B-4C28-9BAB-48B2196E7B2D Q37641401-F9A1CF09-DE13-45B6-A235-347BD754DDCA Q37758502-E69251D6-2381-4DB0-8435-8D69F6738575 Q37778692-BE9BCF9A-3FA3-460C-9EE4-B086F82FB4EC Q37821074-985B0A6B-10C5-4EE4-93E6-1C01B1E00A57 Q37861216-21714E3C-17A2-4BFE-9A8B-4D3DD08031DF Q37952804-2D11698E-EA7B-410E-A28A-61C95C942329

P2860

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

http://www.wikidata.org/entity/Q34034408

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Blockade of programmed death l ...... immunotherapy against melanoma

@ast

Blockade of programmed death l ...... immunotherapy against melanoma

@en

Blockade of programmed death l ...... immunotherapy against melanoma

@nl

type

label

Blockade of programmed death l ...... immunotherapy against melanoma

@ast

Blockade of programmed death l ...... immunotherapy against melanoma

@en

Blockade of programmed death l ...... immunotherapy against melanoma

@nl

prefLabel

Blockade of programmed death l ...... immunotherapy against melanoma

@ast

Blockade of programmed death l ...... immunotherapy against melanoma

@en

Blockade of programmed death l ...... immunotherapy against melanoma

@nl

P1433

Q34034408-0AB37692-2E5A-462C-B500-60060773F722

P1476

Q34034408-A015851F-C9E0-4DBB-871C-C8848BB9BC1F

P2093

Q34034408-25589973-DF00-4128-BC51-DC1838B14FF0

Q34034408-C5F2935E-8165-4551-ADA8-84D23FF55BF6

Q34034408-DA30CE6A-DA89-4928-95B9-48DF81075C3C

P2860

Q34034408-15EFF2EF-5DBA-426A-BDB3-2801B79BEE43

Q34034408-1FA41C36-7131-4851-BECC-D60F04E8BBDB

Q34034408-45F8E822-5647-4FED-92A1-73170D06EF9B

Q34034408-5A5B8167-4CDE-418F-B488-DD2AC8D5F379

Q34034408-64CFD8F3-7A86-46B3-A030-B8DB21BA1528

Q34034408-6D5BC22C-F85C-4160-97D6-4C4D95E5092E

Q34034408-6DA63875-55D8-4758-90B7-CAB8C1C8A50C

Q34034408-6E2D7522-82F1-417A-8E48-205D74BBD15D

Q34034408-7044A0FB-3260-48D8-9FFF-9F2145A23EE8

Q34034408-730C683A-C297-4F37-9B4C-7EC3AEF11FE0

P304

Q34034408-2702317E-327B-4E29-A07F-D8E466C77991

P31

Q34034408-1D0F6480-5796-4C10-9F4D-CA2B677F500B

P356

Q34034408-4E848F49-3ED2-4814-B27E-135E845CBF8C

P407

Q34034408-92D93097-578B-4A65-B53D-032BF7E64EDB

P433

Q34034408-B7BA58A8-CE13-45C6-8054-49999D1F1277

P478

Q34034408-3253F9DF-F534-467C-A3F3-515DE10D2EFD

P50

Q34034408-9DE45827-188D-4869-AE1B-8466AEC7407A

P577

Q34034408-2233889C-CD05-47B0-A82B-B187E7762796

P5875

Q34034408-DD3AF7C4-681F-4B2C-B518-4781C9C8175A

P698

Q34034408-3B743490-AFE2-4956-AB4B-F19BE794E319

P921

Q34034408-2CB20819-044B-494C-AFD6-BC288D91BF9D

P932

Q34034408-AFA6CB1E-00B9-4C7F-B281-FF7551470328

P356

JIMMUNOL.0904114

P1433

Journal of Immunology

P1476

Blockade of programmed death l ...... immunotherapy against melanoma

@en

P2093

Amy Mackay

http://www.w3.org/2001/XMLSchema#string

James J Mulé

http://www.w3.org/2001/XMLSchema#string

Shari Pilon-Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/ MHC epitopes and strength of their interaction with T cell receptors.

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.

P304

3442-3449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.0904114

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P50

Nasreen A. Vohra

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41656795

http://www.w3.org/2001/XMLSchema#string

P698

20194714

http://www.w3.org/2001/XMLSchema#string

P921

P932

2913584

http://www.w3.org/2001/XMLSchema#string